Published in Bull Math Biol on January 01, 1986
The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother (1997) 2.84
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Res (2000) 1.09
Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer (1991) 1.05
(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR Biomed (2012) 0.95
Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy. J Math Biol (2015) 0.76
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
Kinetics of mammary tumor cell growth and implications for therapy. Cancer (1971) 1.76
Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother Rep (1967) 1.65
Studies on the Photosynthetic Reaction. III. The Effects of Various Inhibitors upon Growth and Carbonate-Fixation in Chlorella Pyrenoidosa. Plant Physiol (1957) 1.59
Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep (1970) 1.54
Establishment of cross-resistance profiles for new agents. Cancer Treat Rep (1983) 1.18
Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. Cancer Chemother Rep (1968) 1.12
Experimental evaluation of potential anticancer agents. XVI. Basic study of effects of certain anticancer agents on kinetic behavior of model bacterial cell populations. Cancer Chemother Rep (1965) 1.12
The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res (1965) 1.09
Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res (1970) 1.06
Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. Semin Hematol (1978) 0.97
Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res (1967) 0.96
Laboratory models: some historical perspective. Cancer Treat Rep (1986) 0.92
Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. Cancer Chemother Rep (1965) 0.92
Adjuvant chemotherapy. Cancer (1978) 0.91
Experimental evaluation of potential anticancer agents. 28. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites. Cancer Chemother Rep (1965) 0.90
Cancer chemotherapy is many things: G.H.A. Clowes Memorial Lecture. Cancer Res (1971) 0.89
Spontaneous AK leukemia (lymphoma) as a model system. Cancer Chemother Rep (1969) 0.89
A quick reference chart on cross resistance between anticancer patients. Cancer Chemother Rep (1972) 0.88
Body Retention of Carbon 14 from Labeled Sodium Bicarbonate. Science (1949) 0.84
Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755. Cancer Chemother Rep (1969) 0.82
Dose intensity versus total dose of chemotherapy: an experimental basis. Important Adv Oncol (1990) 0.81
Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo. Cancer Chemother Rep (1965) 0.81
The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy. Adv Cancer Res (1983) 0.80
Improvement of the model systems. Cancer Res (1969) 0.80
Kinetic behavior versus response to chemotherapy. Natl Cancer Inst Monogr (1971) 0.78
Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep (1984) 0.78
Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia. Cancer Chemother Rep (1969) 0.77
Experimental evaluation of potential anticancer agents. XX. Development of immunity to leukemia L1210 in BDF mice and effects of therapy. Cancer Chemother Rep (1966) 0.77
Thoughts on cancer chemotherapy and combination modality therapy (1974). JAMA (1974) 0.77
Biochemical, biological, pharmacologic, toxicologic, kinetic and clinical (subhuman and human) relationships. Cancer (1968) 0.76
Concepts for controlling drug-resistant tumor cells. Eur J Cancer (1980) 0.76
Historic milestones in cancer biology: a few that are important in cancer treatment (revisited). Semin Oncol (1979) 0.76
Studies on the Photosynthetic Reaction. II. Sodium Formate and Urea Feeding Experiments with Nostoc muscorum. Plant Physiol (1954) 0.75
The "sensitivity" of resting and dividing cells. Cancer Chemother Rep (1970) 0.75
Stepwise progress in the treatment of disseminated cancers. Cancer (1983) 0.75
Frank M. Schabel 1918-1983. Cancer Res (1984) 0.75
Induced mammary carcinoma in the female rat as a drug evaluation system. Cancer Res (1966) 0.75
Experimental evaluation of potential anticancer agents XV. On the relative rates of growth and host kill of "single" leukemia cells that survive in vivo cytoxan therapy. Cancer Res (1966) 0.75
The "sensitivity" of resting and dividing cells. Klin Oczna (1971) 0.75
Spontaneous AK leukemia (lymphoma) as a model for human leukemias and lymphomas. Cancer Chemother Rep 3 (1972) 0.75
Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy. Important Adv Oncol (1985) 0.75
Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774). Cancer Chemother Rep (1967) 0.75
Combination chemotherapy for spontaneous AKR lymphoma. Cancer Chemother Rep 2 (1974) 0.75
Drug control of Ara-C-resistant tumor cells. Med Pediatr Oncol (1982) 0.75
The Folic Acid Activity and Antagonism of Two Structurally Related Derivatives of Benzimidazole. Science (1948) 0.75
Proceedings: Successes and failures at the preclinical level; where now? Proc Natl Cancer Conf (1972) 0.75
Combination therapy: some concepts and results. Cancer Chemother Rep 2 (1974) 0.75
Experimental adjuvant chemotherapy: an overview. Recent Results Cancer Res (1986) 0.75
Indirect inhibition of protein synthesis. Ann N Y Acad Sci (1965) 0.75